Dr. Shannon Offerman, MD | Brookfield ...

Dr. Shannon Offerman

Claim this profile

Ascension Southeast Wisconsin Hospital - Elmbrook Campus

Studies Prostate Adenocarcinoma
Studies Prostate Cancer
9 reported clinical trials
29 drugs studied

Affiliated Hospitals

Image of trial facility.
Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Image of trial facility.
Ascension All Saints Hospital

Clinical Trials Shannon Offerman is currently running

Image of trial facility.

5-Year vs. 10-Year Colonoscopy

for Colorectal Cancer Prevention

This trial aims to determine the best schedule for preventing small, non-dangerous growths in the colon from turning into cancer by regularly checking and removing them.
Recruiting1 award N/A
Image of trial facility.

Hormone Therapy + Radiation

for Prostate Cancer

This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting2 awards Phase 31 criteria

More about Shannon Offerman

Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Shannon Offerman has experience with
  • Degarelix
  • Histrelin
  • Bicalutamide
  • Leuprolide
  • Triptorelin
  • Goserelin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Shannon Offerman specialize in?
Is Shannon Offerman currently recruiting for clinical trials?
Are there any treatments that Shannon Offerman has studied deeply?
What is the best way to schedule an appointment with Shannon Offerman?
What is the office address of Shannon Offerman?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security